In response to the ongoing challenges for cancer care teams due to the COVID-19 pandemic, OncoLens is offering its OncoLens virtual tumor board software at no cost for 60 days after signing a business associate agreement, through May 15, 2020. The module enables cancer care teams to meet virtually, in real time, to discuss treatment options for their cancer patients on a secure, HIPAA-compliant platform. The platform comes equipped with virtual tumor board capabilities such as screen sharing of pathology and radiology images, care coordination, and clinical decision support, including clinical trial matching and evidence-based guidelines. Administrators are able to capture accreditation metrics for Commission on Cancer, National Accreditation Program for Breast Centers, and National Accreditation Program for Rectal Cancer. Users can upload slides, images and pathology, and laboratory and genetics reports. Pathologists can share their screens if they have digital pathology or have microscopes attached to a computer screen. The OncoLens virtual tumor board module can be deployed in a matter of five to seven days. Click here to register for a 30-minute demonstration. Questions can be directed to info@oncolens.com.
Webinars and Sponsored Roundtables — Register Now
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY